Nonresectable Combined Hepatocellular Carcinoma and Cholangiocarcinoma: Analysis of the Response and Prognostic Factors after Transcatheter Arterial Chemoembolization

Kim, Jin Hyoung; Yoon, Hyun Ki; Ko, Gi Young; Gwon, Dong Il; Jang, Cheol Soo; Song, Ho Young; Shin, Ji Hoon; Sung, Kyu Bo

doi:10.1148/radiol.09091076

Cited by 88 publications

(80 citation statements)

References 36 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…B Arterial contrast-enhanced cone-beam C-arm CT axial image and C digital subtraction angiography image obtained at planning hepatic angiography showed corresponding peripheral hypervascularity and interval growth of the mass. D Arterial phase CECT axial image obtained 8 months after radioembolization treatment showed partial response, with significantly decreased enhancement and overall tumor size [3,13,15,31,32]. In the largest report on systemic chemotherapy for cHCC-CC, median OS from diagnosis was a mere 5.6 months [13].…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

Yttrium-90 Radioembolization for Unresectable Combined Hepatocellular-Cholangiocarcinoma

Chan

Sze

Poultsides

et al. 2017

Cardiovasc Intervent Radiol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 98%

“…Liver transplantation for cHCC-CC is similarly limited by high recurrence rates [11,14]. Estimated survival for patients managed by supportive care alone is only 4-6.5 months from time of diagnosis [3,4,12,15].…”

Section: Introductionmentioning

confidence: 99%

Yttrium-90 Radioembolization for Unresectable Combined Hepatocellular-Cholangiocarcinoma

Chan

Sze

Poultsides

et al. 2017

Cardiovasc Intervent Radiol

View full text Add to dashboard Cite

show abstract

“…12 Hypervascular hepatic tumor have a great chance of tumor reponse to TACE because a chemotherapeutic agent and embolic material can be much more effectively and selectively delivered after TACE. 24,25 Given the perception of pancreatic adenocarcinoma as a hypovascular tumor, the efficacy of TACE for hepatic metastasis from recurrent pancreatic adenocarcinoma remains in question. Given the increased angiogensis and stromal volume in hepatic metastatic tumor than those of the primary tumor, some authors suggested that hepatic metastasis from hypovascular tumor (such as colon cancer, or pancreatic adenocarcinoma) can present with hypervascularity on arterial phase CT or US.…”

Section: Discussionmentioning

confidence: 99%

Transcatheter Arterial Chemoembolization for Hepatic Recurrence after Curative Resection of Pancreatic Adenocarcinoma

Kim¹,

Choi²,

Yoon³

et al. 2010

Gut Liver

Self Cite

View full text Add to dashboard Cite

Background/Aims: Despite curative resection, hepatic recurrences cause a significant reduction in survival in patients with primary pancreatic adenocarcinoma. Transcatheter arterial chemoembolization (TACE) has recently been used successfully to treat primary and secondary hepatic malignancy. Methods: Between 2003 and 2008, 15 patients underwent TACE because of hepatic recurrence after curative resection of a pancreatic adenocarcinoma. The tumor response was evaluated based on computed tomography scans after TACE. The overall duration of patient survival was measured. Results: After TACE, a radiographically evident response occurred in six patients whose tumors demonstrated a tumor blush on angiography. Four patients demonstrated stabilization of a hypovascular mass. The remaining five patients demonstrated continued progression of hypovascular hepatic lesions. The median survival periods from the time of diagnosis and from the time of initial TACE were 9.6 and 7.5 months, respectively. Conclusions: TACE may represent a viable therapeutic modality in patients with hepatic recurrence after curative resection of pancreatic adenocarcinoma. (Gut Liver 2010;4: 384-388)

show abstract

“…Combined hepatocellular and cholangiocarcinoma can be effectively treated by transarterial chemoembolization. 31 Because of similar pathogenesis and molecular alterations, studies designed to ascertain whether N-cadherin-positive viral hepatitis-related intrahepatic cholangiocarcinoma can be successfully treated with the methods used to treat hepatocellular carcinoma should be conducted.…”

mentioning

confidence: 99%

Viral hepatitis is associated with intrahepatic cholangiocarcinoma with cholangiolar differentiation and N-cadherin expression

Yuan

Chen

et al. 2011

Modern Pathology

View full text Add to dashboard Cite

Viral hepatitis-associated intrahepatic cholangiocarcinoma is thought to have common disease processes with hepatocellular carcinoma, but until now the histomorphological and genetic features of viral hepatitisassociated intrahepatic cholangiocarcinoma is still unknown. From 2000 to 2010, 170 patients with intrahepatic cholangiocarcinoma who received detailed pathological assessment and regular follow-up at the National Taiwan University Hospital were selected for this study. Of 170 patients, 69 (41%) were positive for hepatitis B and/or C virus. These patients were younger, were more frequently male, and had elevated serum a-fetoprotein levels as compared with seronegative intrahepatic cholangiocarcinoma patients. Grossly these tumors were mostly of the mass-forming type, and histologically, cholangiolar differentiation was more frequently seen. We identified N-cadherin as an immunohistochemical marker strongly associated with hepatitis virus infection. The prevalence of viral hepatitis in patients with N-cadherin-positive intrahepatic cholangiocarcinoma was 75%, and that in N-cadherin-negative patients was only 37%. N-cadherin-positive patients were younger, had elevated a-fetoprotein, and had no hepatolithiasis. All N-cadherin-positive intrahepatic cholangiocarcinomas were of the mass-forming type. N-cadherin positivity was strongly associated with cholangiolar morphology and lack of carcinoembryonic antigen and MUC2 expression, whereas K-RAS mutations were less frequent. Our results indicate that a subgroup of intrahepatic cholangiocarcinoma characterized by cholangiolar differentiation and N-cadherin expression is strongly associated with viral hepatitis.

show abstract

Nonresectable Combined Hepatocellular Carcinoma and Cholangiocarcinoma: Analysis of the Response and Prognostic Factors after Transcatheter Arterial Chemoembolization

Cited by 88 publications

References 36 publications

Yttrium-90 Radioembolization for Unresectable Combined Hepatocellular-Cholangiocarcinoma

Yttrium-90 Radioembolization for Unresectable Combined Hepatocellular-Cholangiocarcinoma

Transcatheter Arterial Chemoembolization for Hepatic Recurrence after Curative Resection of Pancreatic Adenocarcinoma

Viral hepatitis is associated with intrahepatic cholangiocarcinoma with cholangiolar differentiation and N-cadherin expression

Contact Info

Product

Resources

About